COMMUNIQUÉS West-GlobeNewswire

Information relative au nombre total de droits de vote et d’actions composant le capital social au 31 août 2019
02/09/2019
Paris, le 2 septembre 2019 – 18 :00 CET - Pixium Vision (FR0011950641 - PIX), société bioélectronique qui développe des systèmes de vision bionique innovants pour permettre aux patients ayant perdu la vue, de vivre de [...]
Number of voting rights as of August 31, 2019
02/09/2019
Nicox SA Société anonyme with a registered capital of € 29,910,120 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On September 2, 2019, MONTHLY PUBLICATION OF THE [...]
Nombre de droits de vote au 31 août 219
02/09/2019
Nicox SA Société anonyme au capital de 29 910 120 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 2 septembre 2019, PUBLICATION MENSUELLE DU NOMBRE D’ [...]
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults
02/09/2019
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults Study conducted in the United-States aims to consolidate leucocyte GAG and skin GAG content [...]
Inventiva - Le développement d’odiparcil progresse avec le recrutement des premiers patients dans une nouvelle étude biomarqueur menée chez des adultes et enfants atteints de la MPS VI
02/09/2019
Le développement d’odiparcil progresse avec le recrutement des premiers patients dans une nouvelle étude biomarqueur menée chez des adultes et enfants atteints de la MPS VI L’étude menée aux Etats-Unis vise à étayer la [...]
IBA - Transparency notification
02/09/2019
Louvain-la-Neuve, Belgium, September 02, 2019, 17.35 Summary of the notification IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it [...]
IBA – PUBLICATION RELATIVE À UNE NOTIFICATION DE TRANSPARENCE
02/09/2019
Louvain-la-Neuve, Belgique, 2 septembre 2019, 17.35 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir [...]
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America
02/09/2019
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America Lugano, Switzerland, São Paulo, Brazil, and Buenos Aires, Argentina, September 2, 2019 – Helsinn, a [...]
Novo Nordisk A/S – Share repurchase programme
02/09/2019
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 2 September 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the [...]
SAVE THE DATE: JAY MOHR to Return as Headliner for Fullerton Cares ‘Comedy Show for Autism’ – November 16
02/09/2019
FULLERTON, Calif., Sept. 02, 2019 (GLOBE NEWSWIRE) -- With returning headliner JAY MOHR, the Fullerton Cares ‘Comedy Show for Autism’ in support of Fullerton autism charities and special education programs will be at [...]
Germany becomes first launch market for ALK’s tree SLIT-tablet
02/09/2019
ALK’s new tree SLIT-tablet, ITULAZAX ® , has been launched in its first market: Germany Tree pollen allergy is highly prevalent in northern Europe, making Germany a key market for the product In trials, ITULAZAX ® [...]
Transactions under Novozymes’ stock buyback program
02/09/2019
Please read the full announcement in the attached PDF Attachment 2019_33_Stock_Buybackprogram_EN
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
02/09/2019
Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1]; EVALUATE-HF results [...]
135,000 Orion Corporation A shares converted into B shares
02/09/2019
ORION CORPORATION STOCK EXCHANGE RELEASE 2 SEPTEMBER 2019 at 9.30 EEST 135,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 135,000 [...]
Motif Bio and Hercules Capital Amend Loan and Security Agreement
02/09/2019
NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that its [...]
Herantis Pharma publishes newsletter for July-August
02/09/2019
Herantis Pharma publishes newsletter for July-August Herantis Pharma Plc Press release 2 September 2019 at 9:00 am Herantis Pharma plc (“Herantis”) has published its newsletter for July-August 2019. The newsletter is [...]
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019
02/09/2019
Further preclinical and clinical data presentations of its other diabetic eye disease clinical candidates, THR-687 (Pan-RGD Integrin Inhibitor) and THR-317 (anti-PlGF), will also be delivered Leuven, Belgium, 2 [...]
Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%
02/09/2019
BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an important and [...]
Roche presents positive phase III study results for one-dose Xofluza in children with flu
02/09/2019
Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a [...]

Pages